AVIR Q4 2021 Earnings — Atea Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AVIRAtea Pharmaceuticals, Inc.

$501M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$192M+295.2% YoY

Gross Profit

$134M69.9% margin

Operating Income

$121M63.1% margin

Net Income

$117M60.9% margin

EPS (Diluted)

$1.34

QoQ Revenue Growth

+485.7%

Cash Flow

Operating Cash Flow

-$75M

Free Cash Flow

-$75M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$773M

Total Liabilities

$63M

Stockholders' Equity

$710M

Cash & Equivalents

$764M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$192M	$49M	+295.2%
Gross Profit	$134M	$35M	+286.3%
Operating Income	$121M	$21M	+486.9%
Net Income	$117M	$21M	+467.1%